Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Construction in Progress (2016)

Anika Therapeutics has reported Construction in Progress over the past 6 years, most recently at $22.7 million for Q4 2016.

  • Quarterly Construction in Progress rose 101.3% to $22.7 million in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $22.7 million through Dec 2016, up 101.3% year-over-year, with the annual reading at $22.7 million for FY2016, 101.3% up from the prior year.
  • Construction in Progress was $22.7 million for Q4 2016 at Anika Therapeutics, up from $11.3 million in the prior quarter.
  • Over five years, Construction in Progress peaked at $22.7 million in Q4 2016 and troughed at $42270.0 in Q4 2012.
  • The 5-year median for Construction in Progress is $559000.0 (2014), against an average of $6.9 million.
  • Year-over-year, Construction in Progress tumbled 99.84% in 2012 and then skyrocketed 1916.82% in 2015.
  • A 5-year view of Construction in Progress shows it stood at $42270.0 in 2012, then soared by 272.11% to $157292.0 in 2013, then surged by 255.39% to $559000.0 in 2014, then skyrocketed by 1916.82% to $11.3 million in 2015, then soared by 101.3% to $22.7 million in 2016.
  • Per Business Quant, the three most recent readings for ANIK's Construction in Progress are $22.7 million (Q4 2016), $11.3 million (Q4 2015), and $559000.0 (Q4 2014).